Overview

A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer

Status:
Recruiting
Trial end date:
2027-07-01
Target enrollment:
Participant gender:
Summary
This is a multi-site, open-label, Phase II, randomized, trial to compare the efficacy of RO7198457 versus watchful waiting in patients with circulating tumor DNA (ctDNA) positive, surgically resected Stage II/III rectal cancer, or Stage II (high risk)/Stage III colon cancer.
Phase:
Phase 2
Details
Lead Sponsor:
BioNTech RNA Pharmaceuticals GmbH
BioNTech SE